SCHEMBL30288262

SCHEMBL30288262

FC(F)(F)c1cccc(NCC2CCCC2)c1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.61
LMNA P02545 1/20 0.51
ALDH1A1 P00352 3/20 0.50
EPHX2 P34913 1/20 0.50
GAA P10253 3/20 0.48
POLB P06746 1/20 0.48
RAB9A P51151 1/20 0.48
CRHR1 P34998 2/20 0.47
LIPC P11150 1/20 0.45
LIPG Q9Y5X9 1/20 0.45
PIM1 P11309 1/20 0.44
UBE2M P61081 3/20 0.43
DCUN1D1 Q96GG9 3/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1241128 1.00 RXFP1 (0.61) RXFP1LMNAALDH1A1EPHX2GAA
SCHEMBL30288260 0.94 RXFP1 (0.54) RXFP1LMNAALDH1A1EPHX2GAA
SCHEMBL13439179 0.87 RXFP1 (0.49) RXFP1LMNAALDH1A1CRHR1LIPC
SCHEMBL11935445 0.87 RXFP1 (0.49) RXFP1LMNAALDH1A1CRHR1LIPC
SCHEMBL30288286 0.81 RXFP1 (0.44) RXFP1LMNAALDH1A1EPHX2GAA
SCHEMBL1241605 0.80 LIPC (0.46) RXFP1LMNAALDH1A1EPHX2CRHR1
SCHEMBL30288233 0.79 RXFP1 (0.42) RXFP1ALDH1A1CRHR1LIPCLIPG
SCHEMBL1241972 0.78 PIM1 (0.48) ALDH1A1EPHX2GAAPOLBPIM1
SCHEMBL13438988 0.77 CRHR1 (0.48) RXFP1CRHR1LIPCLIPG
SCHEMBL12204104 0.77 MEN1 (0.44) RXFP1LMNAALDH1A1EPHX2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230055237-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS FLATLEY DISCOVERY LAB, LLC 2023-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055237-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, MPST, CRAT RXFP1 931/4885LMNA 2631/4885ALDH1A1 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.